oral semaglutide cardiovascular outcomes soul trial results 2024 2025 Trial Scorecard: SOUL 🔴Cardiovascular outcomes with semaglutide by

Compounded GLP-1s arent the same as the branded versions, though they generally use the same active ingredient

Primarily, when a compounding pharmacy creates a copy of an approved drug which is not subject to a shortage as determined by FDA, the compounder is no longer immune from the federal misbranding and unapproved new drug statutes, both of which could result in FDA enforcement and serious regulatory consequences

The same results were acquired from a separate study with a larger sample size

Flatulence, bloating, and altered bowel habits are commonly reported with GLP-1 drugs and can be a sign that digestion has slowed and the balance of gut bacteria has shifted